ArticleEClinicalMedicine2026
Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis affects at least 60 million people globally, but access to effective biologic treatments is limited, particularly in low- and middle-income countries. This study models the incremental global health and economic impact of large-scale access expansion for adalimumab and ustekinumab biosimilars following their inclusion on the World Health Organization (WHO) Essential Medicines List (EML) for psoriasis, as recommended by the 25th WHO Expert Committee on Selection and Use of Essential Medicines. Methods: An empirical decision-analytic health economic model was developed to estimate the incremental costs and quality-adjusted life-years (QALYs) over a five-year horizon, using a 3% discount rate. The model compared the hypothetical current status quo with an EML expansion scenario for a target population of 8.9 million adults with moderate-to-severe psoriasis refractory to conventional systemic therapies. Findings: Expanded biosimilar access under EML implementation was simulated to generate an incremental 0.625 QALYs per patient at an additional cost of $13,973 USD over five years. Extrapolated to the global target population, this policy could deliver a total health gain of 5.56 million QALYs, with an associated incremental budget impact of $124.35 billion USD over five years. One-way and probabilistic sensitivity analyses confirmed the robustness of these findings: probabilistic analysis mean of 5.67 million QALYs (95% Credible Interval [CrI] 0.38-12.84 million). These findings should be interpreted as upper-bound estimates derived from a simplified model that assumes full access in the eligible population, 60% optimal response, sustained five-year treatment benefit with uniform persistence, no switching or waning efficacy, and full biosimilar costs regardless of response. Interpretation: The recent expansion of the WHO EML for psoriasis to include biosimilars could yield over 5.5 million QALYs globally. The profound health and access implications of the world-wide implementation of this EML expansion will require regional monitoring. Funding: This study was funded by the International League of Dermatological Societies (ILDS). SML is funded by LifeArc and DEBRA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.